157 related articles for article (PubMed ID: 29225246)
1. Acute Arterial Thrombosis during Postoperative Adjuvant Cisplatin-based Chemotherapy for Completely Resected Lung Adenocarcinoma.
Sato C; Okuda K; Tamiya H; Yamamoto K; Hoshina K; Narumoto O; Urushiyama H; Noguchi S; Amano Y; Watanabe K; Mitani A; Kage H; Tanaka G; Yamauchi Y; Takai D; Nagase T
Intern Med; 2018 Feb; 57(4):557-561. PubMed ID: 29225246
[TBL] [Abstract][Full Text] [Related]
2. Recurrent peripheral arterial thrombosis induced by cisplatin and etoposide.
Cool RM; Herrington JD; Wong L
Pharmacotherapy; 2002 Sep; 22(9):1200-4. PubMed ID: 12222560
[TBL] [Abstract][Full Text] [Related]
3. Arterial thrombosis after chemotherapy with cisplatin, vinblastine and methotrexate.
Molloy RG; Welch GC; Drury JK; Abel BJ
Br J Clin Pract; 1995; 49(1):50-1. PubMed ID: 7742194
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
[TBL] [Abstract][Full Text] [Related]
5. [Adjuvant chemotherapy for non-small cell lung cancer].
Okamoto T; Ichinose Y
Gan To Kagaku Ryoho; 2006 Dec; 33(13):1985-90. PubMed ID: 17197740
[TBL] [Abstract][Full Text] [Related]
6. Split-dose cisplatin and vinorelbine as adjuvant chemotherapy for completely resected non-small cell lung cancer.
Hirai F; Seto T; Shimokawa M; Inamasu E; Toyozawa R; Toyokawa G; Yoshida T; Shiraishi Y; Takenaka T; Yamaguchi M; Takenoyama M; Ichinose Y
Anticancer Res; 2014 Feb; 34(2):927-31. PubMed ID: 24511034
[TBL] [Abstract][Full Text] [Related]
7. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
Imaizumi M;
Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
[TBL] [Abstract][Full Text] [Related]
8. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.
Kumar P; Herndon J; Langer M; Kohman LJ; Elias AD; Kass FC; Eaton WL; Seagren SL; Green MR; Sugarbaker DJ
Cancer; 1996 Jun; 77(11):2393-9. PubMed ID: 8635112
[TBL] [Abstract][Full Text] [Related]
9. [Postoperative adjuvant therapy in combined lung cancer treatment].
Cicenas S; Piscikas DA; Jakubauskiene R
Medicina (Kaunas); 2004; 40 Suppl 1():156-60. PubMed ID: 15079128
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.
Mizugaki H; Fujiwara Y; Yamamoto N; Yagishita S; Kitazono S; Tanaka A; Horinouchi H; Kanda S; Nokihara H; Tsuta K; Asamura H; Tamura T
Jpn J Clin Oncol; 2014 Sep; 44(9):835-40. PubMed ID: 25097183
[TBL] [Abstract][Full Text] [Related]
11. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer.
Früh M; Rolland E; Pignon JP; Seymour L; Ding K; Tribodet H; Winton T; Le Chevalier T; Scagliotti GV; Douillard JY; Spiro S; Shepherd FA
J Clin Oncol; 2008 Jul; 26(21):3573-81. PubMed ID: 18640938
[TBL] [Abstract][Full Text] [Related]
12. Postoperative adjuvant therapy for completely resected early-stage non-small cell lung cancer.
Kato H; Tsuboi M; Kato Y; Ikeda N; Okunaka T; Hamada C
Int J Clin Oncol; 2005 Jun; 10(3):157-64. PubMed ID: 15990962
[TBL] [Abstract][Full Text] [Related]
13. [Postoperative adjuvant chemotherapy for non-small cell lung cancer].
Okamoto T; Ichinose Y
Gan To Kagaku Ryoho; 2005 Jun; 32(6):765-9. PubMed ID: 15984513
[TBL] [Abstract][Full Text] [Related]
14. Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy.
Koriyama H; Ishii G; Yoh K; Neri S; Morise M; Umemura S; Matsumoto S; Niho S; Ohmatsu H; Tsuboi M; Goto K; Ochiai A
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1163-70. PubMed ID: 25446816
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program.
Filipits M; Pirker R; Dunant A; Lantuejoul S; Schmid K; Huynh A; Haddad V; André F; Stahel R; Pignon JP; Soria JC; Popper HH; Le Chevalier T; Brambilla E
J Clin Oncol; 2007 Jul; 25(19):2735-40. PubMed ID: 17602078
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.
Ramsden K; Laskin J; Ho C
Clin Oncol (R Coll Radiol); 2015 Jul; 27(7):394-400. PubMed ID: 25800720
[TBL] [Abstract][Full Text] [Related]
17. EGFR gene copy number gain is related to high tumor SUV and frequent relapse after adjuvant chemotherapy in resected lung adenocarcinoma.
Koh Y; Jang B; Jeon YK; Kim TM; Lee SH; Kim DW; Chung DH; Kim YT; Kim YW; Heo DS
Jpn J Clin Oncol; 2011 Apr; 41(4):548-54. PubMed ID: 21247966
[TBL] [Abstract][Full Text] [Related]
18. Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.
Ikeda N; Nagase S; Ohira T
Ann Thorac Cardiovasc Surg; 2009 Jun; 15(3):144-9. PubMed ID: 19597387
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of platinum combination chemotherapy re-challenge for relapsed patients with non-small-cell lung cancer after postoperative adjuvant chemotherapy of cisplatin plus vinorelbine.
Imai H; Shukuya T; Yoshino R; Muraki K; Mori K; Ono A; Akamatsu H; Taira T; Kenmotsu H; Naito T; Murakami H; Tomizawa Y; Takahashi T; Takahashi K; Saito R; Yamamoto N
Chemotherapy; 2013; 59(4):307-13. PubMed ID: 24480845
[TBL] [Abstract][Full Text] [Related]
20. Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab.
Haratake N; Toyokawa G; Tagawa T; Kozuma Y; Matsubara T; Takamori S; Akamine T; Yamada Y; Oda Y; Maehara Y
Anticancer Res; 2017 Oct; 37(10):5713-5717. PubMed ID: 28982891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
